Selective glycoimmuno-targeting for cancer therapy

Información del proyecto

SweetAim

Identificador del acuerdo de subvención: 716220

DOI

10.3030/716220

Proyecto cerrado

Fecha de la firma de la CE 28 Noviembre 2016

Fecha de inicio 1 Diciembre 2016

Fecha de finalización 30 Noviembre 2022

Financiado con arreglo a

• EXCELLENT SCIENCE - European Research Council (ERC)

Coste total

€ 1 479 995,00

Aportación de la UE

€ 1 479 995,00

Coordinado por

TEL AVIV UNIVERSITY
Israel

Periodic Reporting for period 4 - SweetAim (Selective glycoimmuno-targeting for cancer therapy)

Período documentado: 2021-06-01 hasta 2022-11-30

Resumen del contexto y de los objetivos generales del proyecto

Cancer is a leading cause of death worldwide and new therapies are still needed. The primary objective of this proposal is to design a novel cancer therapeutic approach and to address the challenges faced by the study of carbohydrates immune recognition. It is based on findings that some tumor-associated carbohydrates can be targeted for cancer therapy. We investigated the potential of robust effective targeting of tumor-carbohydrates with antibodies both in vitro and in vivo. This research is has provided tools for designing novel therapeutics, imaging and diagnostics for cancer and for other chronic inflammation-related diseases, that are very important to reduce cancer burden for the benefit of society.

Trabajo realizado desde el comienzo del proyecto hasta el final del período abarcado por el informe y los principales resultados hasta la fecha

We investigated carbohydrates as targets for antibody therapy in cancer. We explored the different factors that affect carbohydrate binding and recognition and developed several methods to improve antibody recognition and cancer killing potential both through passive therapy, as well as through active cancer vaccine design.

Avances que van más allá del estado de la técnica e impacto potencial esperado (incluida la repercusión socioeconómica y las implicaciones sociales más amplias del proyecto hasta la fecha)

We have already published fifteen papers and submitted 8 patents related to the use of antibodies for cancer diagnostics and therapy.

072120-nutri-red-meat-cancer-risk-low-resolution.jpg